Kidney Week

Abstract: TH-PO1255

A Randomized, Placebo-Controlled Phase 2 Trial of a Long-Acting, C3-Targeting siRNA in IgA Nephropathy

Session Information

• Late-Breaking Research Posters
  October 22, 2026 | Location: Exhibit Hall A, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Pharmacology (PharmacoKinetics, -Dynamics, -Genomics)

• 1900 Pharmacology (PharmacoKinetics, -Dynamics, -Genomics)

Authors

• Lv, Jicheng, Peking University First Hospital, Beijing, China

Jicheng Lv, MD

• Chang, Jie, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China

Jie Chang

• Wu, Henglan, Jiaxing First Hospital, Jiaxing, China

Henglan Wu, MD

• Yan, Rui, Guizhou Medical University Affiliated Hospital, Guiyang, China

Rui Yan

• Hou, Shuang, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China

Shuang Hou, MD, MS

• Li, Guisen, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, China

Guisen Li

• Luo, Qun, Ningbo No.2 Hospital, Ningbo, China

Qun Luo

• Qi, Hualin, Shanghai Pudong Hospital, Shanghai, China

Hualin Qi, MD, PhD

• Zhu, Lingling, Suzhou Rigerna Therapeutics, Ltd., Suzhou, China

Lingling Zhu, MBBS, DM

• Yang, Julia, Suzhou Rigerna Therapeutics, Ltd., Suzhou, China

Julia Yang

• Du, Zhiqiang, Suzhou Rigerna Therapeutics, Ltd., Suzhou, China

Zhiqiang Du, PharmD, CNS, MSH

• Li, Haitao, Suzhou Rigerna Therapeutics, Ltd., Suzhou, China

Haitao Li, PhD

• Huang, Yuanyu, Suzhou Rigerna Therapeutics, Ltd., Suzhou, China

Yuanyu Huang, PhD

• Zhang, Hong, Peking University First Hospital, Beijing, China

Hong Zhang, MD, PhD

Background

Complement activation contributes to kidney injury and progression in immunoglobulin A Nephropathy (IgAN). RG002C0106 is a Complement C3 siRNA molecular for sustained complement modulation with infrequent dosing. We report clinical results from the first randomized, placebo-controlled Phase 2 trial study（NCT07305974）of a C3-targeting siRNA in IgAN.

Methods

This study enrolled 34 adults with biopsy-confirmed IgAN into a 24-week randomized, placebo-controlled period, followed by a 96-week open-label extension. Participants were randomized the ratio of 4:1 receiving RG002C0106 regimens and placebo. An independent third party conducted the interim analysis and provided the summary result.

Results

RG002C0106 demonstrated a remarkably rapid onset of action, with response evident by 2 weeks, and deepening through 12 weeks. Placebo-adjusted mean 24h uPCR reductions were 50% in the low-dose regimen and 52%–67% across three high-dose regimens. Serial first-morning-void uPCR showed a clear downward trend. Notably, significant hematuria improvements occurred at Week 12. RG002C0106 was generally well tolerated, without serious adverse events or serious infections as of the cutoff.

Conclusion

This is the 1^st randomized, placebo-controlled Phase 2 Trial and show rapid proteinuria reduction by 2 weeks and a deep response reaching up to 60% at 12 weeks (results of 24 weeks will update on Oct 15^th,2026) . The rapid onset, depth of response, preliminary safety profile, and infrequent dosing may differentiate RG002C0106 from existing IgAN therapies. RG002C0106 could provide a foundational complement-targeted treatment in IgAN treatment paradigm.

Funding

• Commercial Support – Rigerna Therapeutics (Beijing) Co., Ltd. Rigerna Therapeutics Co., Ltd.